Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
25 studies found for:    (menopause OR postmenopause) [CONDITION ] ((hormone therapy) OR HRT) [TREATMENT ] | Open Studies
Show Display Options
Rank Status Study
1 Recruiting The Impact of Hormone Therapy on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder
Condition: Menopausal Syndromes
Interventions: Drug: Tibolone;   Drug: Estradiol & medroxyprogesterone acetate
2 Recruiting Estrogen Diastolic Heart Failure
Condition: Menopause
Interventions: Drug: Estradiol/Norethindrone acetate;   Drug: Placebo
3 Recruiting Efficacy Study of Progesterone Tablet in Post-menopausal Women
Condition: Menopause
Intervention: Drug: Progesterone
4 Recruiting Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women
Condition: Menopause
Interventions: Drug: oral estradiol 0.5 mg;   Drug: oral estradiol 1.0 mg;   Drug: oral progesterone 100 mg
5 Recruiting Females, Aging, Metabolism, and Exercise
Condition: Obesity
Interventions: Drug: GnRH agonist;   Behavioral: Supervised cardiovascular exercise;   Drug: Placebo
6 Recruiting Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
Conditions: Cognitive Impairment;   Executive Dysfunction;   Endothelial Dysfunction;   Cardiovascular Disease
Interventions: Drug: Leuprolide acetate;   Drug: Estradiol;   Drug: Medroxyprogesterone;   Drug: Placebo
7 Recruiting Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women
Condition: Breast Cancer
Intervention:
8 Recruiting Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy
Conditions: Atrophic Vaginitis;   Menopause
Interventions: Device: CO2 fractionated vaginal laser;   Drug: Estrogens, Conjugated (USP)
9 Not yet recruiting Oral Contraceptives as Infertility Treatments for Premature Ovarian Failure
Conditions: Primary Ovarian Insufficiency;   Menopause, Premature
Intervention: Drug: Drospirenone and ethinyl estradiol combination (Yasmin)
10 Recruiting PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline;   Procedure: Diagnostic Imaging: 18F-FES PET/CT - Baseline;   Procedure: Diagnostic Imaging: 18F-FES PET/CT - 3 month follow-up
11 Not yet recruiting Sustainability of Vaginal Estrogen Therapy in Postmenopausal Women
Conditions: Atrophy of Vagina;   Postmenopause
Intervention: Drug: Gynoflor
12 Not yet recruiting Postprandial Lipidemia After a Meal With Different Types of Fat, Estrogen Treatment, Age and Gender in Healthy Subjects
Condition: Menopause
Interventions: Drug: Estrogens;   Other: Placebo
13 Not yet recruiting Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy
Conditions: Atrophic Vaginitis;   Menopause;   Vulvovaginal Atrophy
Interventions: Drug: Vaginal progesterone;   Drug: Placebo
14 Recruiting Estrogen Therapy as Prevention in the Progression of Aneurysm (EPPA) Trial
Conditions: Cerebral Aneurysm;   Menopause;   Treatment
Interventions: Drug: Estradiol;   Drug: Placebo
15 Recruiting Transdermal Testosterone Nanoemulsion in Women Libido
Condition: Menopause
Interventions: Drug: Testosterone;   Drug: Placebo
16 Recruiting Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery
Conditions: Estrogen;   Menopause;   Pelvic Floor Disorders;   Surgery
Interventions: Drug: Premarin;   Drug: Vagifem
17 Recruiting Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women
Condition: Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Intervention: Drug: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
18 Recruiting Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women
Condition: Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women
Intervention: Drug: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
19 Recruiting Tibolone and Placebo in Adjunct to Antidepressant Medication for Women With Menopausal Depression
Condition: Menopausal Depression
Intervention: Drug: Tibolone
20 Not yet recruiting Phase I Clinical Trial of PK, PD and Safety Evaluations of Testosterone Gel 1% for 28 Days in Post-menopausal Women.
Condition: Post-menopausal Period
Intervention: Drug: Testosterone

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.